Stockscreener 앱 받기
30.64
1.78%
-0.575
전일 마감가:
$31.21
열려 있는:
$31.18
하루 거래량:
3.60M
Relative Volume:
0.34
시가총액:
$35.15B
수익:
$16.88B
순이익/손실:
$666.71M
주가수익비율:
49.96
EPS:
0.6132
순현금흐름:
$251.19M
1주 성능:
-3.87%
1개월 성능:
+14.04%
6개월 성능:
+79.79%
1년 성능:
+43.92%
1일 변동 폭
$30.47
$31.44
1주일 범위
$30.47
$31.73
52주 변동 폭
$12.46
$31.99
테바 ADR Stock (TEVA) Company Profile
명칭
Teva Pharmaceutical Industries Ltd Adr
전화
972 (3) 914-8213
주소
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
TEVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
ZTS
Zoetis Inc
|
124.73 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.58 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.985 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
UTHR
United Therapeutics Corp
|
490.87 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
테바 ADR Stock (TEVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-12-05 | 개시 | Scotiabank | Sector Outperform |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-05-28 | 개시 | Truist | Buy |
| 2025-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-07-10 | 업그레이드 | Argus | Hold → Buy |
| 2024-03-08 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-11-27 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-06 | 업그레이드 | UBS | Sell → Neutral |
| 2023-05-25 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-18 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-01-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-06-14 | 재개 | UBS | Neutral |
| 2022-05-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-05-04 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-03-25 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | 다운그레이드 | Argus | Buy → Hold |
| 2021-10-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 개시 | Oppenheimer | Perform |
| 2020-08-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 재개 | Goldman | Neutral |
| 2020-06-01 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-24 | 재개 | Citigroup | Neutral |
| 2020-04-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Edward Jones | Hold → Sell |
| 2019-11-12 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-10-17 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-08-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 개시 | Wolfe Research | Peer Perform |
| 2019-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-07-05 | 업그레이드 | Argus | Hold → Buy |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-06-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-03-07 | 재개 | UBS | Buy |
모두보기
테바 ADR 주식(TEVA)의 최신 뉴스
The Truth About Teva Pharmaceutical (ADR): Is Wall Street Sleeping on This Comeback Play? - AD HOC NEWS
Celiac Disease Market Report 2025-2035: Drivers, Challenges, Opportunities, Industry Trends and Case Studies - GlobeNewswire Inc.
What Do Analysts Think About Teva Pharmaceutical Industries (TEVA)? - Finviz
Has Teva’s Surging Share Price Outpaced Its Long Term Recovery Prospects? - Sahm
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive - Sahm
J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play - Finviz
Teva Pharma stock hits 52-week high at 30.45 USD - Investing.com India
Teva (TEVA): Assessing Valuation After a 65% Three‑Month Share Price Surge - Sahm
BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz
FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz
Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? - Finviz
Has Teva’s 80% One Year Surge Run Ahead of Its Fundamental Valuation in 2025? - Sahm
Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 - Sahm
Teva Releases Q4 2025 Aide Memoire - Sahm
Teva (NYSE:TEVA) Valuation Check After New Schizophrenia Drug Filing and Growing Growth Optimism - Sahm
Teva’s FDA Filing For Once-Monthly Schizophrenia Drug Might Change The Case For Investing In TEVA - Sahm
Teva Pharma stock hits 52-week high at 29.81 USD By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at 29.81 USD - Investing.com
TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia - Finviz
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play - Finviz
Teva (NYSE:TEVA) Valuation Check After Strong Q3, Margin Targets and Deleveraging Drive a Sharp Share Price Rebound - Sahm
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz
Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm
Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm
Teva stock hits 52-week high at 26.38 USD - Investing.com
Teva Rise Innovation Platform Might Change The Case For Investing In Teva Pharmaceutical Industries (TEVA) - Sahm
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm
Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges - Finviz
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Shares: Cheap or Risky? - fostersleader.com
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? - Finviz
Teva Pharma stock hits 52-week high at $25.96 By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at $25.96 - Investing.com
Teva (NYSE:TEVA) Valuation: Assessing Upside After Positive Earnings and Updated Long-Term Growth Targets - Sahm
Are Medical Stocks Lagging Teva Pharmaceutical Industries (TEVA) This Year? - sharewise.com
Teva Pharmaceutical ADR Clears Key Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily
Why Teva Pharmaceutical Stock Rocked the Market Today - Finviz
Teva Fires on All Cylinders as Innovation and Pipeline Support Growth and Cost-Controls Lift Margins - Morningstar
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook - Sahm
Earnings call transcript: Teva beats Q3 2025 forecasts, stock surges - Investing.com
Teva stock hits 52-week high at 23.07 USD - Investing.com
Teva stock hits 52-week high at 23.07 USD By Investing.com - Investing.com Philippines
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November - Sahm
Earnings call transcript: Teva’s Q2 2025 shows steady growth, stock rises - Investing.com
테바 ADR (TEVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.88%
자본화:
|
볼륨(24시간):